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Abstract
One of the biggest challenges of the world in this 21st century is to cure  
HIV-AIDS. In Present scenario different antiviral drugs are available in the market 
to reduce the worse condition and manage improved survival rate. These drugs are 
manageable but their bioavailability, lower permeability and poor half life of the 
drugs have limitations. If the drug is preferred in higher dosage in AIDS patients, 
the drug leads to toxicity and adverse effects to patients and increase resistant 
against HIV & if the drug is preferred in lower dose along with nano carriers it will 
reach the target area for beneficial effect, therefore drugs Lacking of Knowledge in 
Potent Drug delivery systems is due to instability, chemical degradation and tissue 
barrier difficulties are reasons to reach drug target successfully. In this scenario 
Nanotechnology based antiretroviral drugs delivery holds drug and will provide to 
cure AIDS. Nanotechnology based deliver system Nanocarriers like Liposomes, den-
drimers, Nanoparticles, Polymeric Micelles, Nanovesicles, Nanoemulsion provide 
the way to deliver drug to targeting tissue. Nanobased carriers revolutionized the 
field of Pharmaceutics and Pharmaco Kinetic’s in target drug delivery. The present 
study depicts nano based ARV drug provides increase efficiency with less adverse 
effects to control HIV. Like same way we can provide and increase nanobased drug 
delivery capacity to other available HIV drugs.
Keywords: HIV, AIDS, Antiretroviral Drugs, Nanocarriers, Nanotechnology,  
Drug delivery
1. Introduction
One of the most severe public health issues in the world is the Human 
Immunodeficiency Virus (HIV), the virus that causes Acquired Immunodeficiency 
Syndrome. HIV-AIDS remains one of the most difficult conditions to treat in 
the 21st century. However, multiple antiretroviral medications are present in the 
present situation, rendering the disease chronic rather than worse, which helps to 
improve the survival rate. According to the Statistical survey of WHO 2019 (World 
Health Organization), there are 38 million people living with HIV infection from 
that 1.7 million people newly added with HIV- infection in 2019 and 6.9 million 
people died from this 68% people accessed to Antiretroviral therapy [1]. In the late 
20th century, it was reported that two strains of HIV diverge from SIV (Simian 
immunodeficiency Virus) from which HIV-1 spread across the world, and HIV-2 
is more prominent in Africa [2]. HIV invades the mucosal membrane, destroys 
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the immune system, leaving a wide variety of bacteria, viruses, fungi, protozoa 
vulnerable to infection in the host body. By exchanging body fluids due to blood 
transfusion, organ transplantation, physical intercourse, from affected parent to 
offspring, HIV infection propagates. One of the key sources of entry through the 
mucosal surfaces is the sexual transmission. The primary path of heterosexual HIV 
transmission is the female genital tract [3]. Sexual transmission via the rectal route 
is also a major issue that, due to its physiology, renders it more vulnerable to HIV 
infection [4]. Immune cells, i.e. macrophages and dendritic cells found in the sub-
epithelial layer of the vagina or cervix mucosa are the main targets of HIV infection 
[5] in Figure 1.
During copulation, it moves by semen or other biological fluids that penetrate 
the stratified squamous epithelium or vaginal columnar epithelium to invade the 
target cell. HIV has a glycoprotein called gp120 on the surface of the viral coat, 
which attaches to the T-helper lymphocyte transmembrane protein receptor CD4 or 
chemokine receptor CCR5, CXCR4, and infects the cell [6]. Through endocytosis, 
HIV infects the host cell and fuses with the host cell membrane and releases into 
the host cytoplasm, it undergoes reverse transcription by incorporating proviral 
DNA into the host genomes. It then releases new viral particles that come out of it 
to infect the other cells. It infects macrophages and depletes the quantity of CD4+ 
cells that are the distinctive characteristics of an infection with HIV [7]. The use 
of multiple genes by HIV viruses (a) Main genes: gag, pol, and env (b) regulatory 
genes: tat, rev, nef, vif, vpr, and vpu, boost the productivity and hijacking the host’s 
cellular system and develops its offspring to infect other cells [8]. Viral particles 
linger in the key after active infection in anatomical location such as dendritic cells, 
Figure 1. 
Pictorial representation of HIV particle invasion.
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macrophages, bone marrow, lymph nodes, spleen, lung, Central nervous system 
(astrocytes, microglial cells) [9–11]. When it remains in the CNS and induces a 
major loss in neural networks and eventually it leads to severe problems, such as 
HIV-associated dementia (HAD) If the patient is not, Well treated, it’s going to die 
in 5–10 years (Figure 2) [12].
Various antiretroviral medications are used in the present scenario. Accessible in 
the market in a different mix, depends on the point of infection. High antiretroviral 
activity Therapy (HAART) is used to treat HIV/AIDS. It was introduced in 1996 and 
requires a mixture of at least three antiretroviral (ARV) medications. This treat-
ment has been used to prolong the lifespan of HIV-infected patients [13]. However, 
this treatment is used to treat some of the infections Extension, but complete 
recovery has not yet been achieved as these ARV medications have certain draw-
backs, such as mild water solubility, limited controlled release, low half-life reactiv-
ity, reduced blood barrier permeability, poor bioavailability is one of the major 
issues [14, 15]. ARV operates on the theory of blocking and inhibiting pathways, 
depending on the stage of the HIV cycle. Inhibitor of reverse transcriptase Blocks 
the action of the reverse transcriptase enzyme that prevents the conversion of viral 
RNA to DNA. Various nucleotide analogs drugs which incorporated in between the 
reverse Tran scripting chain in the host cytoplasm and terminate the process and 
non-nucleotide analogs drug bind to the reverse transcription enzyme and block 
the life cycle [16]. Various forms of AIDS treatment regimens are available that are 
available on the market. It has been prescribed. However, it is difficult to choose 
the right mixture of ARV products because of different considerations such as drug 
properties, drug tolerance status, patient reactivity, drug costing, drug toxicity, or 
some other adverse drug effect [17]. The biggest downside of the ARV treatment is 
the shorter period of availability in the bloodstream of the body in such a way that 
the viral particle at the location of reservoirs such as CNS, lymph nodes, and lungs 
Figure 2. 
Pictorial art representing ligand receptor/co-receptor interaction between the HIV virus and Cd4 cell.
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is less exposed to the drug, such that higher doses of the viral particle are needed 
for a sustained period of time that develops resistance to the HIV strain [18]. The 
reservoir also includes latently infected cells, including CD4+ T-cells, Monocytes, 
macrophage lineage carrying incorporated transcription of the provirus silencing 
within the genome that might also re-infect the patient due to activation of the 
proviral genome [19]. In order to resolve such problems and drawbacks, nano-based 
drug delivery technologies, nano-medicines, and other nano-based strategies play 
a key role in drug effectiveness, drug reactivity, drug target accuracy, minimizing 
drug toxicity and negative impacts, and various major challenges currently facing 
ARV drugs in the present context.
2.  Current anti-retro viral drug available in market for HIV-AIDS 
treatment
In present situation, HAART (Highly active anti-retroviral Therapy) regimen 
work on the principles by blocking replication process, reverse transcription, pro-
tein maturation process and viral-DNA integration process in to the host chromo-
somes. To inhibit this all process various class of drugs are available in the market 
which include Nucleotide reverse transcription inhibitors (NRTI), Non nucleotide 
reverse transcriptase inhibitors (NNTRI), integrase inhibitors, protease inhibitors 
as mention below in Error: Reference source not found (Table 1):
Non-nucleoside reverse transcriptase inhibitors (NNRTI)
Generic names Abbreviations Brand name Manufacturer
Efavirenz EFV Sustiva® Bristol-Myers Squibb
Etravirine TMC125 Intelence® Tibotec
Nevirapine NVP Viramune® Boehringer Ingelheim
Delavirdine DLV Rescriptor® ViiV Health care.
Reverse transcriptase inhibitors (NRTI)
Didanosine ddI Videx® Bristol-Myers Squibb
Zalcitabine ddC HIVID® Roche
Lamivudine 3TC Epivir® GlaxoSmithKline
Abacavir ABC Ziagen® GlaxoSmithKline
Zidovudine AZT Retrovir ® GlaxoSmithKline
Tenofovir TDF Vemlidy® Gilead Sciences
Stavudine d4T Zerit® Bristol-Myers Squibb
Integrase inhibitors
Generic names Brand name Manufacturer
Raltegravir Isentress® Merck
Dolutegravir Tivicay® ViiV Health care.
Protease inhibitors
Generic names Abbreviations Brand name Manufacturer
Saquinavir SQV Invirase® Roche
Atazanavir ATV Reyataz® Bristol-Myers Squibb
Indinavir IDV Crixivan® Merck
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3. World of Nanobiotechnology in field of drug delivery
The field of Nanobiotechnology that emerges with the great modern manufacturing 
for higher performance of drug due the scope of the Nanoscale process (1-100 nm). 
With the advent of nanotechnologies, it revolutionizes drug delivery in the field of 
pharmaceuticals. The fundamental theory is to modulate the pharmacokinetics of the 
chemical molecule that has deserved to eliminate HIV from the body without damag-
ing the body. It also increases the bio-distribution and bioavailability of the drug to 
expose the virus particle for a longer duration with a higher goal precision. Being Nano-
sized, the Nano-material drug reacts differently than the conventional drugs, because 
of their decrease in scale and, they have a healing impact within the living environment. 
Nelfinavir NFV Viracept® Agouron 
Pharmaceuticals
Drug combination Brand name Manufacturer
Lopinavir + Ritonavir Kaletra® Abbott Labs
Lamivudine + Zidovudine Combivir® GlaxoSmithKline
Abacavir + Lamivudine Trizivir® GlaxoSmithKline
Tenofovir + Emtricitabine Truvada® Gilead Sciences




Market Available ARV drugs for HAART.
Figure 3. 
Pictorial representation of Different Nano-systems.
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The encased drug carried by the Nano-systems governs its, absorption, distribution, 
and excretion on the basis of its surface charges present on the Nano-systems due to its 
physical and chemical properties [20, 21]. Application of nanotechnology to the delivery 
of ARV drugs Holds the potential to treat AIDS and it could be beneficial Drugs at the 
anatomical reservoir site and also raise the half-life of drugs [22]. It has become possible 
to use nanotechnology for increased delivery of badly water-soluble drugs, selective 
delivery of drugs to particular cells or tissues, Intracellular transmission of macromol-
ecules [23]. Nano-carriers give a range of advantages, such as control of drugs degrada-
tion, drug specificity and delivery of biological products molecules, such as proteins, 
peptides, oligopeptides, oligonucleotides, etc. Nanocarriers are now using it to solve the 
limitation of therapeutic uses, such as drug delivery, bioavailability of drugs, drug con-
formation stability, physicochemical stability, improved transmission  permeability, drug 
clearance, cellular absorption, reduction of immunogenic reaction (Figure 3) [24, 25].
Different Nano-system strategies can be utilized as shown in the Error: Reference 
source not found for ARV drug entrapment which holds to cure HIV infection.
4. Liposomes
Liposomes became the first type of Nanomaterial in 1976, functionalized for drug 
delivery applications [26]. A liposome is a tiny microscopic vesicle that is made up of 
the phospholipid bilayers that are normally encircled by the watery centre. It is ben-
eficial to hold hydrophilic drugs by trapping with in the centre, while the hydrophobic 
drug is inserted into the lipid bilayer [27]. The scale of the liposomes can be between 
25 nm and multiple microns, offering the benefit of permeability (Figure 4).
Figure 4. 
Pictorial art of Liposomes for targeted drug delivery.
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Human or synthetic phospholipids, along with cholesterol and additionally lipids, 
protein or peptide fragments, are used in their preparation. Liposomes, upon enter-
ing the living organism, realize that they are alien particles surrounded by mono-
nuclear phagocytic cells, such as macrophages, so that liposomes are a beneficial 
carrier of the anti-HIV drug to the infected cell. As a result, liposomes can increase 
the effectiveness of the anti-HIV medication by lowering its side effect [28]. There 
are three types of liposomes, namely small uni-lamellar vesicles, large uni-lamellar 
vesicles, and multi-lamellar vesicles. In their natural form, liposomes are trapped by 
the reticulo-endothelial system and easily clear from circulation. Liposomes interact 
with the cell surface in a number of ways. The first is lipid exchange, which helps 
to exchange lipid molecules between liposomes and cell membranes. The second is 
adsorption, which diffuses across the cell membrane in the encapsulated substance 
within the liposome. Third, liposomes can, by fusion, transfer their encapsulated 
material to the cell membrane [29]. And foremost important characteristic of 
liposomes, it is engulfed up by the cell through endocytosis [30].
4.1 Liposomal ARV drug formulation for anti-HIV effect
Zidovudine drug is reverse transcriptase inhibitor which is amphiphilic drug, 
loaded into liposomes resulted in major improvements in the pharmacokinetic prop-
erties and distribution of tissues, including higher levels of distribution in reticulo-
endothelial system and brain organs, longer half-life and lower average clearance of 
it relative to conventional zidovudine solution. Therefore, the approach to pro-drug 
liposomes can lead to reduced toxicity and improved efficacy of zidovudine-based 
HIV therapy [28]. The liposomal loaded zalcitabine system (2′,3′-dideoxycytidine, 
ddc) was examined in a mouse macrophage cell line that demonstrates high intracel-
lular absorption due to anionic loading of liposomes [31]. The liposome of the phos-
phorylated form of zalcitabine, tested it in a murine-acquired immunodeficiency 
syndrome model that arrays chemical stability, improved retention entrapment, and 
decreased viral load in the mononuclear phagocyte system in both spleen and bone 
marrow [32]. Several in vitro and in vivo experiments have been undertaken by trap-
ping ARV drugs such as acyclovir, indinavir, zidovudine, and lamivudine into the 
permuted liposomal structure, which shows 12 folds higher amount in blood plasma 
as compare to conventional drug by utilizing elastic liposomes in rat model, skin 
permeation of zidovudine improved 18-fold relative to simple drugs, this indicates 
a high effectiveness of transdermal flux relative to free drugs and higher deposition 
in the reticulo-endothelial organ system following the launch of zidovudine-loaded 
elastic liposomes trans-dermal. This suggests a greater permeability of the liposomal 
composition in rat model [33]. For lymphatic’s targeting, the surface of liposomes 
was coordinated by charges and site-specific ligands to facilitate lymphatic, promi-
nently lymph node and spleen localization. The particle-charged liposomes were 
formed using stearylamine, dicetyphosphate, and mannose conjugate. Evaluating 
these three compounds, fluorescent microscopy indicates a greater position of man-
nose conjugate than negative or positive liposomes, this shows the enhanced target-
ing of lymphatic’s in AIDS chemotherapy [34]. Liposomes are quickly phagocytised 
by macrophages, in order to improve the extended circulation time and bioavailabil-
ity of the drug the surface is changed by hydrophilic molecules such as polyethene 
glycol, PEGylated liposomes with targeting ligand derived from HIV gp120 guided 
monoclonal antibody F10 and seen as novel approaches to the battle against HIV-1. 
These Nano-immuno-liposomes display greater and longer antiviral efficacy than 
free drugs or drugs that encapsulate non-targeted liposomes [35]. Magnetic lipo-
somes containing azidothymidine 5′-triphosphate, the average size of these magnetic 
liposomes 150 nm, are prepared using phosphatidylcholine and cholesterol with 
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a magnetite loading efficiency of 54 per cent and 45.3 per cent. It is researched to 
verify transmigration through the in vitro blood–brain barrier model and monocyte 
mediated transport by adding external magnetic field. The outcome of the apparent 
permeability of magnetic azidothymidine liposomes was 3 times higher than free 
azidothymidine [36]. Indinavir filled with mannosylated liposomes containing βD-1 
Thiomannopyranoside residues covalently coupled to dimyristoyl Phosphatidyl 
ethanolamine (DMPE), which was also incorporated with di-steroylphosphatidyl-
choline and cholesterol, was used to attack the mononuclear phagocyte function 
(J774.A1 macrophage cell line). This liposome showed approximately 88.7 per cent 
of entrapment efficacy. Important levels of the drug have been identified in macro-
phage rich tissues such as the liver, spleen, and lungs relative to liposomes and free 
drugs [37]. Cell-derived liposomes demonstrate greater and more effective targeting. 
It is orchestrated from the cytoplasmic membranes of the cell expressing CCR5, 
the human receptor for gp120 located mainly on the surface of HIV-infected cells 
and HIV-virion, which display a substantial 60% reduction in the viability of the 
HIV-infected model cell due to binding and nullifying infectivity [38]. PEGylated 
liposomal transmission to mammalian cells in culture demonstrated sustained 
release with encapsulation efficiency of approximately 33 per cent. In cell viability 
tests of Jurkat T- cell, lower cytotoxicity was found relative to non-PEGylated 
liposomes [39]. Immune-liposomes filled with heparin active serine Antithrombin 
III (hep-AIII) protease inhibitor injected into the non-human primate system model. 
The outcome indicates a steady decrease of more than 1(10) log in plasma viral load 
that concludes hep-AIII as a rescue or replacement agent for HIV strain immune to 
standard ARV drugs [40]. Glycan-Modified HIV NFL Envelope Trimer-Liposome 
vaccine formulation showed broad generation of neutralizing Antibody in modal, 
which hold proof for immunogenic vaccine development to combat AIDS [41]. The 
use of liposomes to prevent the spread of HIV through sexual transmission has been 
confirmed. The structure of the mixture consisted of liposomes that acted as decoys 
allowing the HIV virus to bind to liposomes instead of host cells. Some formulations 
contain un-conjugated liposomes whose physicochemical properties make it possible 
to bind to the HIV virus or to change the ligand that binds to the HIV virus has also 
been documented. The liposomes were created from lipids picked from the commu-
nity consisting of cationic lipids, anionic lipids, neutral lipids, zwitter ionic lipids, 
and various combinations.
4.2 Dendrimer
The dendrimer consists of Dendron’s, a small branching unit that includes an 
internal and a periphery end group, a polymeric nanostructure consisting of mul-
tiple branching units in a layer by layer pattern that characterizes the size, growth 
and microenvironment within it (Figure 5) [42].
Dendrimer contains space within the Dendron that can be used for drug trap-
ping, selective drug release, defense against environmental destruction, precise 
targeting. Dendrimer with significant numbers of peripheral groups and inner 
cavities are possible vectors for chemical drugs, peptides and HIV inhibition genes. 
These compounds are either capable of interacting with peripheral groups or are 
encased in dendrimer cavities with hydrogen bonds, electrostatic and hydrophobic 
interactions [43, 44]. Dendrimers can improve the stability of chemical drugs and 
encourage cellular absorption by functional end-groups. In the case of gene therapy, 
Dendrimers can take the place of viruses to transfer interference genes to target 
cells to suppress replication of HIV. The scale of the dendrimer is less than 100 nm 
with less poly dispersity and higher functionality than the traditional polymer with 
the 3-Dimensional architecture. The kernel can be synthesized by ammonia and 
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ethylene diamine encircling highly branched repeaters such as polyether, porphy-
rins, poly-amido-amines, polyphenyl and polyamine acids. Core shell properties are 
mainly based on multivalent surfaces that contain targeting or functional groups. 
Dendrimers have been engineered to interact with unique functional end-groups 
preferably with HIV envelope proteins and receptors on host cells in order to inhibit 
the combination of HIV and host cells and later stages of HIV replication.
4.3 Dendrimer formulation for targeting HIV-AIDS
Following the discovery of the HIV inhibition process, two poly anionic 
Dendrimers BRI2932 (SPL2923) and BRI6195 (SPL6195) were found to inhibit the 
replication of HIV (strain IIIB) in the EC50 at 0.1 and 0.3 μg/mL, respectively, with 
exceptionally low cytotoxicity in the host cells. The gp120 binding assay and the 
virus adsorption assay showed that both substances had an effect on the docking 
of HIV in the host cells. In addition, higher concentrations of SPL2923 (500–2500 
times EC50) could also block later stages of HIV infection. Correspondingly, the 
findings of cellular uptake studies revealed that SPL2923 was capable of intrusion 
into the host cell, while SPL6195 was not [45].
Anti-HIV medication Efavirenz loaded with tuftsin-conjugated fifth-generation 
poly (propylene imine) (T5PP) dendrimer, which reveals the prolonged action of 
the treatment in 24 hours, negligible cytotoxicity and cellular absorption 34.5-fold 
stronger than the free in vitro drug in infected macrophages [46]. Dendriplexes 
produced by 2G-NN16 and siRNAs were used for brain targeting. Transfection 
efficiency assessment and transcytosis by means of an in vitro blood–brain barrier 
(BBB) model on astrocytoma cells (U87MG). Unexpectedly, Dendriplexes devel-
oped at a ratio of 2G-NN16/siRNA of 8 displayed the highest transfection efficiency. 
The siRNAs-dendriplexes have been shown to effectively cross the monolayer 
barrier. Dendriplexes demonstrated a dose-dependent HIV inhibition of up to 85 
per cent of HIV infected U87MG cells [47].
Water-stable cationic carbosilane dendrimers, which are used for drug distri-
bution in the HepG2 cell line and PBMC, display greater interaction with nucleic 
acid through the development of nanoconjugates in different stable pH ranges. 
Nanoconjugates also display a high degree of transfection with oligonucleotide 
anti-HIV in laboratory settings [48]. SPL7013 is one of the anionic dendrimers that 
Figure 5. 
Pictorial art of dendrimer complex for drug delivery.
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contains the divalent benzhydryl amide of L-lysine as the nucleus of naphthalene 
sulfonic acid. Efficacy tests of 5% w/w SPL7013 as an aqueous gel found that the 
single intravaginal dose of the formulation shielded pigtailed macaques from 
infection with the intravaginal (SIV) simian-human immunodeficiency virus 
[49]. Multivalent phosphorous-containing catanionic dendrimers with galactosyl 
ceramide analogs have a significant affinity to the V3 loop of the HIV-1 viral enve-
lope protein gp120, which inhibits viral fusion with the plasma membrane and thus 
serves as an entry inhibitor [50]. Dendrimer may also be considered a potent factor 
in the selective expulsion of HIV.
4.4 FDA approved dendrimer of AIDS
A tropical microbicides, first dendrimer-based drug called VivaGel® has 
been submitted to the US FDA as an investigational novel drug, an aqueous-based 
polyacrylic acid gel containing SPL7013 buffered to physiological pH, a nanoscale 
dendrimeric molecule that binds to viruses and stops them from affecting the 
body’s cells [51] as mention in Figure 6.
5. Nanoparticles
Nanoparticles are small colloidal particles of size ranges (10-100 nm) [52]. They 
have the ability for precise targeting of drugs with controlled release, depending 
on their size and polymer structure. Nanoparticles are expected to improve the 
composition and effectiveness of medications with some physiochemical weakness 
of low stability and solubility [53]. Owing to their scale, nanoparticle-based thera-
pies can conveniently be performed using a range of methods (i.e., intravenous, 
subcutaneous, intraperitoneal) and can pass body barriers [54]. Nanoparticles have 
Figure 6. 
Pictorial representation of working function of Viva gel, a tropical microbicide.
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increasingly experimented with selective delivery of ARV drugs to achieve modu-
lated pharmacokinetics, improved potency, reduced systemic toxicity, and adverse 
effects.
5.1 Polymeric nanoparticles
A polymeric nanoparticle can be produced as per a favorable approach to the 
targeted delivery of ARV drugs. Various polymers are used for the construction of 
anti-HIV polymeric nanoparticles such as poly (lactic acid) (PLA), poly (lactic-
co-glycolic acid) (PLGA), poly (alkyl) cyanoacrylate, poly (ethylene glycol-co- 
(lactic-glycolic acid)), poly(caprolactone), and poly(methyl) methacrylate. PLA 
and PLGA have been evaluated and considered safe for human use by the FDA. 
Various drugs can be integrated into these polymers on the basis of their hydrophi-
licity or hydrophobicity, and release properties can easily be changed on the basis 
of specifications.
Zidovudine-loaded polyvinylpyrrolidone (PVP)/stearic acid (SA)-polyethylene 
glycol (PEG) nanoparticles (PSNPs) have been formed using a solvent-emulsifying 
evaporation process. And tested in vitro murine neuro-2a and HeLa cells, which 
display substantial change in cell internalization, stable colloidal suspension, 
enhanced cell absorption, increased half-life, with no cytotoxicity [55]. Saquinavir-
loaded poly (ethylene oxide)-modified poly (epsilon-caprolactone) (PEO-PCL) 
nanoparticle method using a solvent displacement technique. Cellular absorption 
and bio-distribution of PEO-PCL are studied in vitro in human monocyte/macro-
phage (Mo/Mac) THP-1 cell line, which results in a higher accumulation of drugs 
than in aqueous phase form [56].
Electromagnetic intrusion in the permeability of Saquinavir charged nanopar-
ticles studied in human brain micro vascular endothelial cells. Here Nanoparticles 
are used as polybutylcyanoacrylate (PBCA), metylmethacrylate-sulfopropyl-
methacrylate (MMA-SPM) for the study of a human blood–brain barrier model 
that offers higher permeability coefficient across the blood–brain barrier [57]. The 
Chitosan-based nanoparticles loaded with tenofovir were developed to optimize 
its muco adhesion. By decreasing the size from 900 nm to 188 nm of nanoparticle, 
non-cytotoxicity to the vaginal epithelial cell line with improved muco adhesion 6 
percent to 12 percent was reported [58]. This represents polymeric nanoparticles 
demonstrate successful drug delivery in the fight against HIV (Figure 7).
5.2 Solid lipid nanoparticles (SLN) and nano-structured lipid carriers (NCL)
SLN is a thin microscopic structure consisting of physiological lipids that form 
stable Nanoparticles of aqueous surfactant solution. SLN provides a great opportu-
nity to mount ARV drugs because of its small scale, high drug loading ability, slow 
degradation of lipid matrices, large surface reactivity. SLN also promotes sustained 
release, minimizing drug toxicity, dosing frequency and fluctuation of plasma drug 
levels. SLN shows biphasic drug release due to its composition, initial burst due to 
its surface adsorption, and steady release from its lipid center due to progressive 
degradation [59, 60]. SLN of atazanavir-name protease inhibitors was developed by 
Chattopadhyay et al. to verify permeability and, a blood–brain barrier model was 
tested on the human brain micro vascular cell line (hCMEC/D3) that successfully 
results from a higher accumulation of the drug by endothelial cell monolayer than 
the aqueous drug solution with obvious permeability across the barrier membrane 
[61]. Zidovudine palmitate loaded SLN, which accommodates tri laurin as a lipid 
center with a combination of dimyristoyl phosphatidylglycerol resulting in neutral 
charging. It is then modified with polyethene glycol moieties and higher surface 
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phospholipids resulting in better plasma circulation with increased drug half-life 
[62]. Various changes were made to adjust the surface area of the SLN using vari-
ous techniques to achieve higher drug concentration and substantial permeability 
through the blood–brain barrier. Lopinavir SLN was modified using a hot self-nano-
emulsion technique that involves a hot isotropic mixture of stearic acid, poloxamer 
and polyethene glycol in water with rapid cooling, which results in increased 
bioavailability relative to bulk lopinavir [63]. In a perfusion trial, a high level of 
positively charged or negatively charged SLN will result in a high cerebrospinal 
cortical volume that loses the stability of the brain membrane in rats. This helps to 
draw attention to the fact that a high amount of surface load change in the SLN will 
improve the adverse impact on health (Figure 8) [64].
NCL is a fashioned or customized SLN with a solid lipid matrix incorporated 
with liquid lipids with different fatty acid chains in a compromised ordered crys-
talline form that provides higher drug capacity. NCL consists of low-toxic lipid 
molecules that have hydrolytic and oxidative stability. It also indicates the biphasic 
drug release potential for a liquid lipophilic surface containing a drug and a solid 
center with a higher melting point for drug release through diffusion and matrix 
erosion [65, 66]. Preferential in vitro adsorption of proteins such as Apo E to the 
surface of DDI-loaded NLC stabilized using Solutol® HS 15 alone or a ternary 
surfactant method consisting of Solutol® HS 15, Tween® 8.0 and Lutrol® F68 in 
vitro suggests that these NLCs can be used to target Didanosine-loaded to the brain 
[67]. This approach can be a big advancement and is expected to greatly change the 
treatment of HIV. In fact, the ability to administer ARV medications to the CNS 
will make it easier to treat the AIDS dementia complex of HIV/AIDS patients and 
thereby improve their quality of life.
5.3 Inorganic nanoparticles
This class of Nanoparticles contains metal elements such as iron, gold, silver, 
titanium and silica that are currently used in anti-cancer treatment, molecular 
labeling of biomarkers, clinical methods, bioimaging, biosensors. Noble metal 
Figure 7. 
Pictorial art of Solid lipid Nanoparticle carrying embedded drug.
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nanoparticles such as gold, silver, and platinum have been formulated using a 
range of techniques, such as chemical bio-reduction, rough mold, solution-phase 
synthesis, gas-phase deposition, and sol–gel. Silver nanoparticles are becoming 
more common due to their antimicrobial and antiviral effects against hepatitis B, 
herpes simplex virus, respiratory syncytial virus, monkeypox virus and HIV-1 in 
vitro, including clinical isolates and resistant strains [68–72]. Silver nanoparticles 
can bind to the gp120 protein and prevent viral entry, inhibit CD4-mediated 
viral fusion, and interfere with post-invasion phases of the HIV life cycle. Silver 
nanoparticles cause higher antiviral potency and therapeutic index relative to silver 
ion sulfadiazine salts [72]. Conjugated gold nanoparticle with TAK-779 and SDC-
1721 which allow for better anti-HIV activity than its aqueous solution. Inorganic 
nanoparticles have limitations such as cytotoxicity, DNA damage, cellular apoptosis 
triggered by membrane leakage assay and LDH assay [73]. Inorganic nanoparticles 
usually harm the mammalian cells, because elimination of such particles from the 
living system is difficult and create cytotoxicity to the normal health cells with 
the infected cells. Some scientists are seeking to solve this issue with new ways to 
minimize cytotoxicity.
5.4 Polymeric micelles
Polymer micelles are nano-engineered block polymer materials that have core 
shells much like surfactant-based micelles and have been used to enhance perme-
ability, aqueous solubility, chemical corrosion safety, controlled drug release, 
provide hydrophobic surface modification. Polymeric micelles are engineered as a 
hydrophobic heart and a hydrophilic shell that allows anti-HIV drugs to be trapped 
depending on their polarity. In addition, the surface properties of polymeric 
micelles, such as hydrophilic blocks, may be changed by docking antibodies or 
other chemical ligands unique to receptors found in diseases such as HIV-AIDS 
(Figure 9) [74].
A number of pharmaceutical scientists have formulated polymeric ARV-loaded 
mice, such as lamivudine conjugated with stearic acid-g-chitosan oligosaccha-
ride mice, by esterification process that results in pH-dependent drug release, 
low cytotoxic activity, higher cell absorption of HepG2.2.15-infected hepatitis 
Figure 8. 
Pictorial art of nanostructured lipid carrier carrying drug.
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B virus-infected tumor cells [75]. Efavirenz polymeric micelles show substantial 
absorption rate and 3-fold improvement in the pharmacokinetic parameters of 
C-max from 1789 and 2657 ng/ml to 2856 and 7056 ng/ml in single doses between 
20 and 80 mg/kg for healthy adult volunteers [76].
Copolymer: Poly (ethylene glycol) monomethyl ether and poly (ethylene phos-
phoric acid) (mPEG-b-PEPA) uses tenofovir, which varies in the length of the poly 
(ethylene phosphoric acid) chains and the degree of their saturation with tenofo-
vir. Both adducts were found to be more active than conventional tenofovir against 
HIV-1IIIB in MT-4 cells; tenofovir 1:1 adduct with mPEG-b-PEPA49 displayed 
a 14-fold higher selectivity index. Thus, polyether–PEPA and polyester–PEPA 
block copolymers can well serve as scaffolds for the next generation of long-acting 
injectable antiretroviral formulations [77].
5.5 Nanocrystal
Nanocrystal drug itself may be a nano-sized drug particle that could be dis-
persed in aqueous or non-aqueous media. Drug Nanocrystals are mostly developed 
using approaches that promote a top-down approach or a bottom-up approach. 
Top-down techniques, such as media milling and high-pressure homogenization, 
are the most favored methods for the generation of nanocrystals because they are 
ideal for large-scale processing. Nanocrystal medication has longer colloidal stabil-
ity, prolonged and continuous targeting due to expanded surface area. Nanoscale 
pure drug engineering is produced by means of an extremely hydrophobic drug 
that is strenuous to administer as an intravenous solution or by means of drugs 
with a rate of dissolution-limited oral bioavailability. Using a media milling pro-
cedure, Baret et al. formulated Rilpivirine nanocrystals of 200, 400 and 800 nm 
and inserted into mice and dogs via intramuscular and intra subcutaneous route 
and their pharmacokinetic activity was controlled. Experimentally, each therapy 
results in substantial detectable levels of rilpivirine up to 90 days in dogs and 
3 weeks in mice suggesting success in long-term HIV prophylaxis. The author’s 
analysis also indicates that the intra-subcutaneous route of administration shows a 
steady plasma concentration while the intramuscular route shows a criterion have 
been met as well as higher clearance. Rilpivirine amounts have also been observed 
in lymphoid tissues during treatment, promoting the absorption of nanocrystals 
by macrophages [78, 79]. Cabotegravir (CAB) is a newer drug class in the list of 
Viral Integrase Inhibitors, nearing to FDA approval, nano-formulated fatty acid 
ester CAB prodrugs administered to different strains of rats, monkey and various 
invitro model which,results better sustained plasma level for one year, increased 
Figure 9. 
Pictorial art of Polymeric micelles.
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drug accumulation at lymph nodes, blood plasma, liver, enhanced cellular uptake 
and nanocrystal prodrug stability in macrophages, slow drug dissolution rate which 
suggest better half-life [80].
6. Conclusion
An empirical application for anti-HIV therapy in drug delivery system lies 
in the potentiality of a nanotechnology. Development of ARV drugs through 
nanotechnology-based system such as Liposomes, dendrimers, Nanoparticles, 
Polymeric Micelles, Nanovesicles, Nanoemulsion offers efficient & wide targeted 
drug delivery with modulated pharmacokinetics, a higher therapeutic index as 
demonstrated by in vitro and animal’s in vivo studies. These nano-systems provide 
prolong drug circulation, high bioavailability, drug stability, better permeability, 
bioaccumulation in known reservoir sites for HIV-AIDS. It also demonstrated the 
application of ARV nanocarriers to deliver drugs across the blood–brain barrier and 
other impermeable tissue to kill HIV virus. On the basis of HIV lifecycle, diverse 
nanocarriers are surface modified with different moiety to prevent viral fusion with 
intended ARV drug delivery. The majority of works done in the field of nanocarrier 
ARV drug delivery system incorporate a single ARV agent. So, this chapter tends 
to notice about the multidrug delivery system which involves a combination of 
drugs can lead to tremendous efficacious treatment and downgrading of resistance 
profiles. Hence, nanotechnology provides a multifunctional system for scaling up 
therapeutic approaches with innovative formulation to fulfill diverse biological 
requirements.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
16
AIDS Updates - Recent Advances and New Perspectives
[1] WHO (Global Health Observatory 
Data Repository 2019). Available at: 
https://www.who.int/data/gho/data/
themes/hiv-aids Accessed on 16 
January 2021.
[2] Wertheim, J. O., & Worobey, M. 
(2009). Dating the Age of the SIV 
Lineages That Gave Rise to HIV-1 and 
HIV-2. PLoS Computational Biology, 
5(5), e1000377. doi: 10.1371/journal.
pcbi.1000377
[3] Pauwels, R., & De Clercq, E. 
Development of vaginal microbicides 
for the prevention of heterosexual 
transmission of HIV. Journal of acquired 
immune deficiency syndromes and 
human retrovirology: official 
publication of the International 
Retrovirology Association, 1996; 11(3), 
211-221.
[4] McGowan, I. Rectal microbicides: a 
new focus for HIV prevention. Sexually 
Transmitted Infections, 2008; 84(6), 
413-417.
[5] Boggiano, C., & Littman, D. R. HIV’s 
Vagina Travelogue. Immunity, 2007; 
26(2), 145-147.
[6] Littman D. R. Chemokine receptors: 
keys to AIDS pathogenesis. Cell, 1998; 
93(5), 677-680.
[7] McArthur, J. C., Brew, B. J., &Nath, 
A. Neurological complications of HIV 
infection. The Lancet. Neurology, 2005; 
4(9), 543-555
[8] Arendt, C. W., & Littman, D. R. HIV: 
Master of the host cell. Genome 
Biology,2001; 2(11), REVIEWS1030.
[9] Chauveau L, Donahue DA, Monel B, 
Porrot F, Bruel T, Richard L, et al. HIV 
fusion in dendritic cells occurs mainly at 
the surface and is limited by low CD4 
levels. J Virol. (2017) 91: e01248–e01217. 
doi: 10.1128/JVI.01248-17
[10] Wu L, KewalRamani VN. Dendritic-
cell interactions with HIV: infection and 
viral dissemination. Nat Rev Immunol. 
(2006) 6:859-868. doi: 10.1038/nri1960
[11] Wallet C, De Rovere M, Van 
Assche J, Daouad F, De Wit S, Gautier V, 
et al. Microglial cells: the main HIV-1 
reservoir in the brain. Front Cell Infect 
Microbiol. (2019) 9:362. doi: 10.3389/
fcimb.2019.00362
[12] Stoddart, Cheryl & Reyes, Richard. 
Models of HIV1 disease: A review of 
current status. Drug Discovery Today: 
Disease Models. 2006; 3: 113-119.
[13] Lin J. H. Role of pharmacokinetics in 
the discovery and development of 
indinavir. Advanced drug delivery 
reviews, 1999; 39(3): 33-49.
[14] Musacchio, T., &Torchilin, V. P. 
Recent developments in lipid-based 
pharmaceutical nanocarriers. Frontiers 
in bioscience (Landmark edition), 
2011;16: 1388-1412.
[15] 15.Mueller, B. U., Sleasman, J., 
Nelson, R. P., Jr, Smith, S., Deutsch, P. J., 
Ju, W., Steinberg, S. M., Balis, F. M., 
Jarosinski, P. F., Brouwers, P., Mistry, G., 
Winchell, G., Zwerski, S., Sei, S., Wood, 
L. V., Zeichner, S., &Pizzo, P. A . A 
phase I/II study of the protease inhibitor 
indinavir in children with HIV 
infection. Paediatrics, 1998; 102(1 Pt 1), 
101-109.
[16] Rohan, L., &Mallipeddi. Progress in 
antiretroviral drug delivery using 
nanotechnology. International Journal 
of Nanomedicine, 2010; 533-547.
[17] Hammer, S. M., Eron, J. J., Jr, Reiss, 
P., Schooley, R. T., Thompson, M. A., 
Walmsley, S., Cahn, P., Fischl, M. A., 
Gatell, J. M., Hirsch, M. S., Jacobsen, D. 
M., Montaner, J. S., Richman, D. D., 
Yeni, P. G., Volberding, P. A., & 
International AIDS Society-US. 
References
17
Nanotechnology Based Drug Delivery for HIV-AIDS Treatment
DOI: http://dx.doi.org/10.5772/intechopen.97736
Antiretroviral treatment of adult HIV 
infection: 2008 recommendations of the 
International AIDS Society-USA panel. 
JAMA, 2008; 300(5), 555-570.
[18] Varatharajan, L., & Thomas, S. A. 
The transport of anti-HIV drugs across 
blood-CNS interfaces: summary of 
current knowledge and recommen 
dations for further research. Antiviral 
Research, 2009; 82(2), A99–A109.
[19] Redel, L., Le Douce, V., Cherrier, T., 
Marban, C., Janossy, A., Aunis, D., Van 
Lint, C., Rohr, O., & Schwartz, C. HIV-1 
regulation of latency in the monocyte-
macrophage lineage and CD4+ T 
lymphocytes. Journal of leukocyte 
biology, 2010; 87(4), 575-588.
[20] Li, S. D., & Huang, L. 
Pharmacokinetics and biodistribution 
of nanoparticles. Molecular 
Pharmaceutics, 2008; 5(4), 496-504.
[21] LaVan, D. A., Lynn, D. M., & 
Langer, R. Moving smaller in drug 
discovery and delivery. Nature reviews. 
Drug discovery. 2002; 1(1), 77-84.
[22] Amiji, M. M., Vyas, T. K., & Shah, 
L. K. Role of nanotechnology in HIV/
AIDS treatment: the potential to 
overcome the viral reservoir challenge. 
Discovery medicine,2006; 6(34): 
157-162.
[23] Kumar, L., Verma, S., Prasad, D. N., 
Bhardwaj, A., Vaidya, B., & Jain, A. K. 
Nanotechnology: a magic bullet for HIV 
AIDS treatment. Artificial cells, 
nanomedicine, and biotechnology,2015; 
43(2): 71-86.
[24] Sharma, P., &Garg, S. Pure drug 
and polymer-based nanotechnologies 
for the improved solubility, stability, 
bioavailability and targeting of anti-HIV 
drugs. Advanced drug delivery reviews, 
2010; 62(4): 491-502.
[25] Takeuchi, H., Yamamoto, H., & 
Kawashima, Y. Mucoadhesive 
nanoparticulate systems for peptide 
drug delivery. Advanced drug delivery 
reviews, 2001;47(1): 39-54.
[26] Langer R. Polymers for the 
sustained release of proteins and other 
macromolecules. Nature. 1976; 
263:797-800.
[27] Sharma, A. Liposomes in drug 
delivery: Progress and limitations. 
International Journal of Pharmaceutics, 
1997;154(2): 123-140.
[28] Jin, S. X., Bi, D. Z., Wang, J., Wang, 
Y. Z., Hu, H. G., & Deng, Y. H. 
Pharmacokinetics and tissue 
distribution of zidovudine in rats 
following intravenous administration of 
zidovudine myristate loaded liposomes. 
Die Pharmazie,2005; 60(11): 840-843.
[29] Chopra, S., Venkatesan, N., 
&Betageri, G. V. (2013). Liposomes as 
nanocarriers for anti-HIV therapy. Drug 
Delivery and Translational Research, 
3(5), 471-478.
[30] Lasic DD. Liposomes in gene 
delivery. New York: CRC Press; 1997. 
p. 67-112.
[31] Makabi-Panzu, B., Gourde, P., 
Désormeaux, A., & Bergeron, M. G. 
Intracellular and serum stability of 
liposomal 2′,3′-dideoxycytidine. Effect 
of lipid composition. Cellular and 
molecular biology (Noisy-le-Grand, 
France), 1998; 44(2): 277-284.
[32] Oussoren, C., Magnani, M., 
Fraternale, A., Casabianca, A., 
Chiarantini, L., Ingebrigsten, R., 
Underberg, W. J., & Storm, G. (1999). 
Liposomes as carriers of the 
antiretroviral agent dideoxycytidine-5′-
triphosphate. International journal of 
pharmaceutics, 1999; 180(2):  
261-270.
[33] Jain, S., Tiwary, A. K., & Jain, N. K. 
Sustained and targeted delivery of an 
anti-HIV agent using elastic liposomal 
formulation: mechanism of action. 
AIDS Updates - Recent Advances and New Perspectives
18
Current drug delivery, 2006; 3(2): 
157-166.
[34] Kaur, C. D., Nahar, M., & Jain, N. K. 
Lymphatic targeting of zidovudine 
using surface-engineered liposomes. 
Journal of drug targeting,2008; 16(10), 
798-805.
[35] Clayton, R., Ohagen, A., Nicol, F., 
Del Vecchio, A. M., Jonckers, T. H., 
Goethals, O., Van Loock, M., Michiels, 
L., Grigsby, J., Xu, Z., Zhang, Y. P., 
Gutshall, L. L., Cunningham, M., Jiang, 
H., Bola, S., Sarisky, R. T., &Hertogs, K. 
Sustained and specific in vitro 
inhibition of HIV-1 replication by a 
protease inhibitor encapsulated in 
gp120-targeted liposomes. Antiviral 
Research, 2009; 84(2), 142-149.
[36] Saiyed, Z. M., Gandhi, N. H., & 
Nair, M. P Magnetic nanoformulation of 
azidothymidine 5′-triphosphate for 
targeted delivery across the blood-brain 
barrier. International journal of 
nanomedicine,2010; 5, 157-166.
[37] Dubey, V., Nahar, M., Mishra, D., 
Mishra, P., & Jain, N. K. Surface 
structured liposomes for site-specific 
delivery of an antiviral agent-indinavir. 
Journal of Drug Targeting, 2010; 19(4): 
258-269.
[38] Bronshtein, T., Toledano, N., 
Danino, D., Pollack, S., &Machluf, M. 
Cell-derived liposomes expressing CCR5 
as a new targeted drug-delivery system 
for HIV infected cells. Journal of 
controlled release: official journal of the 
Controlled Release Society, 2011; 151(2): 
139-148.
[39] Ramana, L. N., Sharma, S., 
Sethuraman, S., Ranga, U., & Krishnan, 
U. M. Investigation on the stability of 
saquinavir loaded liposomes: 
implication on stealth, release 
characteristics and cytotoxicity. 
International journal of pharmaceutics, 
2012;431(1-2): 120-129.
[40] Asmal, M., Whitney, J. B., 
Luedemann, C., Carville, A., Steen, R., 
Letvin, N. L., &Geiben-Lynn, R. In vivo 
anti-HIV activity of the heparin-
activated serine protease inhibitor 
antithrombin III encapsulated in 
lymph-targeting immune liposomes. 
PloS one,2012; 7(11): e48234.
[41] Dubrovskaya, V., Tran, K., 
Ozorowski, G., Guenaga, J., Wilson, R., 
Bale, S., ... & Wyatt, R. T. (2019). 
Vaccination with glycan-modified HIV 
NFL envelope trimer-liposomes elicits 
broadly neutralizing antibodies to 
multiple sites of vulnerability. 
Immunity, 51(5), 915-929.
[42] Tomalia, D. A., & Fréchet, J. M. J. 
(2001). Introduction to the dendritic 
state. Dendrimers and other dendritic 
polymers, 3-40.
[43] Svenson, S., &Tomalia, D. A. 
(2012). Dendrimers in biomedical 
applications—reflections on the field. 
Advanced drug delivery reviews, 64, 
102-115.
[44] D'Emanuele, A., & Attwood, D. 
(2005). Dendrimer–drug interactions. 
Advanced drug delivery reviews, 57(15), 
2147-2162.
[45] Witvrouw, M., Fikkert, V., 
Pluymers, W., Matthews, B., Mardel, K., 
Schols, D., ... &Pannecouque, C. 
(2000). Polyanionic (ie, polysulfonate) 
dendrimers can inhibit the replication 
of human immunodeficiency virus by 
interfering with both virus adsorption 
and later steps (reverse transcriptase/
integrase) in the virus replicative cycle. 
Molecular Pharmacology, 58(5), 
1100-1108.
[46] Bosman, A. W., Janssen, H. M., & 
Meijer, E. W. About Dendrimers: 
Structure, Physical Properties, and 
Applications. Chemical Reviews,1999; 
99(7): 1665-1688.
19
Nanotechnology Based Drug Delivery for HIV-AIDS Treatment
DOI: http://dx.doi.org/10.5772/intechopen.97736
[47] Jiménez, J. L., Gómez, R., Briz, V., 
Madrid, R., Bryszewsk, M., de la Mata, 
F. J., & Muñoz-Fernández, M. Á. 
Carbosilanedendrimers as carriers of 
siRNA. Journal of Drug Delivery Science 
and Technology,2012; 22(1): 75-82.
[48] de Las Cuevas, N., Garcia-Gallego, 
S., Rasines, B., de la Mata, F. J., Guijarro, 
L. G., Muñoz-Fernández, M. Á., & 
Gómez, R. In vitro studies of water-
stable cationic carbosilanedendrimers as 
delivery vehicles for gene therapy 
against HIV and hepatocarcinoma. 
Current medicinal chemistry, 2012; 
19(29): 5052-5061.
[49] Jiang, Y. H., Emau, P., Cairns, J. S., 
Flanary, L., Morton, W. R., McCarthy, 
T. D., & Tsai CC. SPL7013 gel as a 
topical microbicide for the prevention 
of vaginal transmission of SHIV89.6P in 
macaques. AIDS research and human 
retroviruses, 2005; 21(3): 207-213.
[50] Dezzutti, C. S., James, V. N., Ramos, 
A., Sullivan, S. T., Siddig, A., Bush, T. J., 
... & Hart, C. E. (2004). In vitro 
comparison of topical microbicides for 
prevention of human immunodeficiency 
virus type 1 transmission. Antimicrobial 
agents and chemotherapy, 48(10), 
3834-3844.
[51] Rupp, R., Rosenthal, S. L., & 
Stanberry, L. R. (2007). VivaGel 
(SPL7013 Gel): a candidate dendrimer--
microbicide for the prevention of HIV 
and HSV infection. International 
journal of nanomedicine, 2(4), 561-566.
[52] International Organization for 
Standardization (ISO). 
Nanotechnologies —Vocabulary — Part 
2: Nano-objects. ISO/TS 80004-
2:2015 (2015).
[53] Panyam, J., &Labhasetwar, V. 
Biodegradable nanoparticles for drug 
and gene delivery to cells and tissue. 
Advanced drug delivery reviews, 2003; 
55(3): 329-347.
[54] Blanco, E., Shen, H., & Ferrari, M. 
(2015). Principles of nanoparticle 
design for overcoming biological 
barriers to drug delivery. Nature 
biotechnology, 33(9), 941.
[55] Joshy, K. S., Snigdha, S., Anne, G., 
Nandakumar, K., Laly. A., P., &Sabu, T. 
Poly (vinyl pyrrolidone)-lipid based 
hybrid nanoparticles for anti-viral drug 
delivery. Chemistry and Physics of 
Lipids, 2018; 210: 82-89.
[56] Shah, L. K., &Amiji, M. M. 
Intracellular delivery of saquinavir in 
biodegradable polymeric nanoparticles 
for HIV/AIDS. Pharmaceutical 
Research, 2006; 23(11): 2638-2645.
[57] KUO, Y., & KUO, C. 
Electromagnetic interference in the 
permeability of saquinavir across the 
blood-brain barrier using 
nanoparticulate carriers. International 
Journal of Pharmaceutics, 2008; 
351(1-2): 271-281.
[58] Meng, J., Sturgis, T. F., &Youan, B. 
B. Engineering tenofovir loaded 
chitosan nanoparticles to maximize 
microbicide mucoadhesion. European 
journal of pharmaceutical sciences: 
official journal of the European 
Federation for Pharmaceutical Sciences, 
2011; 44(1-2): 57-67.
[59] Martins, S., Sarmento, B., Ferreira, 
D. C., &Souto, E. B. Lipid-based 
colloidal carriers for peptide and protein 
delivery- -liposomes versus lipid 
nanoparticles. International journal of 
nanomedicine, 2007;2(4): 595-607.
[60] Rawat, M., Singh, D., Saraf, S., 
&Saraf, S. Lipid carriers: a versatile 
delivery vehicle for proteins and 
peptides. Yakugakuzasshi: Journal of the 
Pharmaceutical Society of Japan, 2008; 
128(2): 269-280.
[61] Chattopadhyay, N., Zastre, J., Wong, 
H. L., Wu, X. Y., &Bendayan, R. Solid 
AIDS Updates - Recent Advances and New Perspectives
20
lipid nanoparticles enhance the delivery 
of the HIV protease inhibitor, 
atazanavir, by a human brain 
endothelial cell line. Pharmaceutical 
Research, 2008; 25(10): 2262-2271.
[62] Heiati, H., Tawashi, R., & Phillips, 
N. C. (1998). Solid lipid nanoparticles as 
drug carriers. International Journal of 
Pharmaceutics, 1998; 174(1-2): 71-80.
[63] Negi, J. S., Chattopadhyay, P., 
Sharma, A. K., & Ram, V. Development 
of solid lipid nanoparticles (SLNs) of 
lopinavir using hot self-nano-
emulsification (SNE) technique. 
European journal of pharmaceutical 
sciences: official journal of the 
European Federation for Pharmaceutical 
Sciences, 2013; 48(1-2): 231-239.
[64] Lockman, P. R., Koziara, J. M., 
Mumper, R. J., & Allen, D. D. 
Nanoparticle surface charges alter 
blood-brain barrier integrity and 
permeability. Journal of drug targeting, 
2004;12(9): 635-641.
[65] Abbasalipourkabir, R., Salehzadeh, 
A., & Abdullah, R. Characterization 
and stability of nanostructured lipid 
carriers as drug delivery system. 
Pakistan journal of biological sciences: 
PJBS, 2012; 15(3): 141-146.
[66] Zhang, X., Liu, J., Qiao, H., Liu, H., 
Ni, J., Zhang, W., & Shi, Y. (2010). 
Formulation optimization of 
dihydroartemisinin nanostructured 
lipid carrier using response surface 
methodology. Powder Technology, 2010; 
197(1-2): 120-128.
[67] Kasongo, K. W., Jansch, M., Müller, 
R. H., & Walker, R. B. Evaluation of the 
in vitro differential protein adsorption 
patterns of didanosine-loaded 
nanostructured lipid carriers (NLCs) 
for potential targeting to the brain. 
Journal of liposome research,2011; 
21(3): 245-254.
[68] Lu, L., Sun, R. W., Chen, R., Hui, C. 
K., Ho, C. M., Luk, J. M., Lau, G. K., 
&Che, C. M. Silver nanoparticles inhibit 
hepatitis B virus replication. Antiviral 
therapy, 2008; 13(2): 253-262.
[69] Baram-Pinto, D., Shukla, S., Perkas, 
N., Gedanken, A., &Sarid, R. Inhibition 
of herpes simplex virus type 1 infection 
by silver nanoparticles capped with 
mercapto ethane sulfonate. Bioconjugate 
Chemistry, 2009; 20(8): 1497-1502.
[70] Sun, Lova& Singh, Ankur &Vig, 
Komal & Pillai, Shreekumar& Singh, 
Shree. (2008). Silver Nanoparticles 
Inhibit Replication of Respiratory 
Syncytial Virus. Journal of Biomedical 
Nanotechnology. 2008;4: 149-158.
[71] Rogers, J. V., Parkinson, C. V., Choi, 
Y. W., Speshock, J. L., &Hussain, S. M. 
(2008). A Preliminary Assessment of 
Silver Nanoparticle Inhibition of 
Monkeypox Virus Plaque Formation. 
Nanoscale Research Letters, 2008;3(4): 
129-133.
[72] Lara, H. H., Ayala-Nuñez, N. V., 
Ixtepan-Turrent, L., & Rodriguez-
Padilla, C. (2010). Mode of antiviral 
action of silver nanoparticles against 
HIV-1. Journal of nanobiotechnology, 
2010; 8:1.
[73] Braydich-Stolle, L., Hussain, S., 
Schlager, J. J., & Hofmann, M. C. 
(2005). In vitro cytotoxicity of 
nanoparticles in mammalian germline 
stem cells. Toxicological sciences: an 
official journal of the Society of 
Toxicology, 2005;88(2): 412-419.
[74] Nagasaki, Y., Yasugi, K., Yamamoto, 
Y., Harada, A., &Kataoka, K. (2001). 
Sugar-installed block copolymer 
micelles: their preparation and specific 
interaction with lectin molecules. 
Biomacromolecules, 2001;2(4): 
1067-1070.
[75] Li, Q., Du, Y. Z., Yuan, H., Zhang, 
X. G., Miao, J., Cui, F. D., & Hu, F. Q. 
(2010). Synthesis of lamivudine stearate 
and antiviral activity of stearic acid-g-
chitosan oligosaccharide polymeric 
21
Nanotechnology Based Drug Delivery for HIV-AIDS Treatment
DOI: http://dx.doi.org/10.5772/intechopen.97736
micelles delivery system. European 
journal of pharmaceutical sciences: 
official journal of the European 
Federation for Pharmaceutical Sciences, 
2010;41(3): 498-507.
[76] Chiappetta, D. A., Hocht, C., Taira, 
C., &Sosnik, A. (2011). Oral 
pharmacokinetics of the anti-HIV 
efavirenz encapsulated within 
polymeric micelles. Biomaterials, 
2011;32(9): 2379-2387.
[77] Nifant’ev, I., Siniavin, A., Karamov, 
E., Kosarev, M., Kovalchuk, S., Turgiev, 
A., ... &Ivchenko, P. (2021). A New 
Approach to Developing Long-Acting 
Injectable Formulations of Anti-HIV 
Drugs: Poly (Ethylene Phosphoric Acid) 
Block Copolymers Increase the 
Efficiency of Tenofovir against HIV-1 in 
MT-4 Cells. International Journal of 
Molecular Sciences, 22(1), 340.
[78] Baert, L., van ‘tKlooster, G., Dries, 
W., François, M., Wouters, A., 
Basstanie, E., Iterbeke, K., Stappers, F., 
Stevens, P., Schueller, L., Van 
Remoortere, P., Kraus, G., Wigerinck, 
P., & Rosier, J. Development of a 
long-acting injectable formulation with 
nanoparticles of rilpivirine (TMC278) 
for HIV treatment. European journal of 
pharmaceutics and biopharmaceutics: 
official journal of Arbeitsgemeinschaft 
fur PharmazeutischeVerfahrenstechnik
e.V, 2009; 72(3): 502-508.
[79] van ‘tKlooster, G., Hoeben, E., 
Borghys, H., Looszova, A., Bouche, M. 
P., van Velsen, F., &Baert, L. (2010). 
Pharmacokinetics and disposition of 
rilpivirine (TMC278) nanosuspension 
as a long-acting injectable antiretroviral 
formulation. Antimicrobial agents and 
chemotherapy, 2010; 54(5): 2042-2050.
[80] Gauram, N., McMillan, J. M., 
Kumar, D., Bade, A. N., Pan, Q., 
Kulkarni, T. A., ... &Alnouti, Y. (2021). 
Lipophilic Nanocrystal Prodrug-Release 
Defines the Extended Pharmacokinetic 
Profiles of a Year-Long Cabotegravir. 
bioRxiv.
